Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease - 22/09/20
Doi : 10.1016/j.jinf.2020.06.049
Anna Daunt a, b, 1, ⁎, Pablo N. Perez-Guzman a, 1, ⁎, Felicity Liew c, Katharina Hauck a, Ceire E. Costelloe d, Mark R. Thursz b, Graham Cooke a, e, 2, ⁎, Shevanthi Nayagam a, b, 2, ⁎ 
a MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom
b Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, United Kingdom
c Respiratory Medicine, Imperial College Healthcare NHS Trust, United Kingdom
d Global Digital Health Unit, School of Public Health, Imperial College London, United Kingdom
e Department of Infectious Diseases, Imperial College London, United Kingdom
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Keywords : Covid-19, Mortality, Clinical deterioration, Risk score, Remdesivir
Le texte complet de cet article est disponible en PDF.
© 2020
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 81 - N° 4
P. 647-679 - octobre 2020 Retour au numéro
Article précédent
- Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19
- Ying Su, Guo-wei Tu, Min-jie Ju, Shen-ji Yu, Ji-li Zheng, Guo-guang Ma, Kai Liu, Jie-fei Ma, Kai-huan Yu, Yuan Xue, Zhe Luo
- Outbreak of COVID-19 in a nursing home in Madrid
- Emilio Bouza, María Jesús Pérez-Granda, Pilar Escribano, Rocío Fernández-del-Rey, Ignacio Pastor, Zaira Moure, Pilar Catalán, Roberto Alonso, Patricia Muñoz, Jesús Guinea, the Senex-COVID-19 Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.